Post-vaccine antibody levels reduce the risk of COVID-19, including from Omicron

A study published in The Journal of Infectious Diseases by CITF-funded researchers Drs. Brian Grunau, David Goldfarb, and Agatha Jassem (University of British Columbia), and Sheila O’Brien and Steven Drews (both from Canadian Blood Services) shows that higher antibody levels against the original (wild-type) SARS-CoV-2 virus are associated with a significantly reduced risk of subsequent infections with SARS-CoV-2 variants, both preceding and during the Omicron era. The association, however, was weaker during the Omicron wave.